Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, pharmaceuticals company AbbVie (ABBV 1.17%) has earned a coveted five-star ranking.
With that in mind, let's take a closer look at AbbVie and see what CAPS investors are saying about the stock right now.
AbbVie facts
|
Headquarters (founded) |
North Chicago, Ill. (2012) |
|
Market Cap |
$58.3 billion |
|
Industry |
Pharmaceuticals |
|
Trailing-12-Month Revenue |
$18.0 billion |
|
Management |
Chairman/CEO Richard Gonzalez |
|
Trailing-12-Month Operating Margin |
43.8% |
|
Cash/Debt |
$4.6 billion / $0 |
|
Dividend Yield |
1.1% |
|
Competitors |
GlaxoSmithKline |
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 98% of the 108 members who have rated AbbVie believe the stock will outperform the S&P 500 going forward.
Just yesterday, one of those Fools, czheng393, offered a cautiously bullish take on AbbVie:
Spinoff of [Abbott Laboratories]. This will most likely unlock value by allowing the company to be able to focus more on the experimental aspect of it. ... It holds the Humira patent which is due to expire in 2016. But until then, Humira is doing exceptionally well and is a leading brand for arthritis and Crohn's Disease. The drug manufacturing process is long and arduous, therefore we are unsure of the prospects of AbbVie developing another drug that is just as successful as Humira after the patent expiration. Meanwhile, the marketplace is also extremely competitive, with numerous pharmaceuticals vying for market share for their own drugs.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.
